CD64 and Antibiotics in Human Sepsis (CD64SEPLDX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02922998|
Recruitment Status : Unknown
Verified November 2017 by Manfred Weiss, University of Ulm.
Recruitment status was: Recruiting
First Posted : October 4, 2016
Last Update Posted : November 9, 2017
|Condition or disease|
|Antibiotic Resistant Infection Critical Illness SIRS Sepsis|
In the present study, in critically ill patients with suspected infection undergoing application of antibiotics, CD64 and inflammatory plasma markers will be determined on days 1 to 4.
CD64 expression on the surface of neutrophils will be determined by fluorescence activated cell sorter (FACS) and with a new bedside test (LeukoDx).
The purpose of the study is to clarify:
- Is CD64 expression on neutrophils associated with effective antibiotic therapy in critically ill adult patients at risk of sepsis?
- Is CD64 expression associated with distinct plasma parameters of inflammation?
- Do the results of the gold standard CD64 determination by FACS correlate with those of a new bedside test (LeukoDx)?
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Monitoring CD64 on Neutrophils Regarding Effects of Antibiotics in Patients With SIRS Developing Sepsis|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||June 2019|
- CD64 expression on neutrophils measured by LeukoDx [ Time Frame: 1 year ]
- Association of course of CD64 expression with effective antibiotic treatment [ Time Frame: 1 year ]
- CD64 expression on neutrophils measured by FACS [ Time Frame: 1 year ]
- Association of CD64 expression with inflammatory markers [ Time Frame: 1 year ]
- Association of CD64 expression with cell surface markers on monocytes [ Time Frame: 1 year ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02922998
|Contact: Manfred Weiss, MD||49 (0)email@example.com|
|Contact: Marion E Schneider, PhD||: 49 (0)firstname.lastname@example.org|
|Principal Investigator:||Manfred Weiss, MD||Department of Anaesthesiology, University Hospital Ulm; Ulm, Germany 89075|